The dose escalation study was designed to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose, as well as preliminary anti-cancer activity of single agent RXDX-101 in patients with solid tumors with activating alterations in the TrkA, ROS1 or ALK tyrosine kinase receptors. At the time of data cut-off for Dr. Gainor's presentation, 18 patients were enrolled, with 17 having been dosed in six escalating dose cohorts. The preliminary findings show:

the rate of enrollment has increased since Ignyta assumed responsibility for the study from its licensee in late 2013;

no dose limiting toxicities have been observed to date;

seven patients remain on active treatment in the study, with some patients having received 12 cycles of treatment; and

promising signs of antitumor activity have been observed.

Ignyta has filed a Form-8-K with the U.S. Securities and Exchange Commission containing the materials presented by Dr. Gainor.

News-Medical.net - An AZoNetwork Site
Owned and Operated by AZoM.com Limited Copyright 2000-2015

News-Medical.Net provides this medical information service in accordance
with these terms and conditions.
Please note that medical information found
on this website is designed to support, not to replace the relationship
between patient and physician/doctor and the medical advice they may provide.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Find out more here.